Dual-organ toxicity during treatment with nivolumab and ipilimumab in combination with chemotherapy in the first-line treatment of non-small cell lung cancer
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). The combination of nivolumab and ipilimumab with two cycles of chemotherapy improves treatment efficacy; however, this combination therapy is also associated with a high incidence of adverse events. We report a rare and significant case of dual-organ failure following treatment with nivolumab and ipilimumab in a 65-year-old male patient with stage IV lung adenocarcinoma. During treatment with chemotherapy combined with nivolumab and ipilimumab, the patient developed severe diarrhea and was later found to have autoimmune colitis, leading to a suspension of immunotherapy and initiation of steroid treatment. After a brief recovery and partial tumor regression, the patient experienced grade 3 pneumonitis upon resuming nivolumab monotherapy, necessitating intensive treatment and discontinuation of immunotherapy. Following cessation of treatment, the patient’s condition remained stable with no disease progression observed over three months. ICIs can induce non-specific immune activation, resulting in widespread inflammatory effects. Early recognition and prompt treatment with high-dose steroids are essential to prevent rapid deterioration in patients experiencing immune-related adverse events (irAEs). Given the widespread use of ICIs in cancer therapy and ongoing clinical trials, there is a need for increased education on irAE and updated management algorithms for NSCLC patients.
Keywords: NSCLCimmunotherapymulti-organ toxicitypneumonitiscolitis
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022; 17(3): 362–387.
- Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw. 2020; 20(1): e10.
- Obwieszczenie Ministra Zdrowia z dnia 11 grudnia 2023 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 stycznia 2024 r. https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-11-grudnia-2023-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych.
- Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16(9): 563–580.
- Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2): 198–211.
- Nielsen DL, Juhl CB, Chen IM, et al. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treat Rev. 2022; 109: 102440.
- Kubo K, Kato M, Mabe K. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis. Clin Gastroenterol Hepatol. 2017; 15(9): A35–A36.
- Marthey L, Mateus C, Mussini C, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(4): 395–401.
- Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel). 2021; 11(12).
- Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3: 39.
- Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases. 2019; 7(4): 405–418.
- Xie X, Wang L, Li Y, et al. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. Front Immunol. 2022; 13: 879900.
- Brazel D, Lee S, Mahadevan A, et al. Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review. Cureus. 2023; 15(7): e41781.
- Wang H, Guo X, Zhou J, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer. 2020; 11(1): 191–197.
- Carbone D, Ciuleanu TE, Schenker M, et al. First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). J Clin Oncol. 2023; 41(17_suppl): LBA9023–LBA9023.
- Khalid AB, Calderon G, Jalal SI, et al. Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. J Natl Compr Canc Netw. 2022; 20(12): 1316–1320.
- Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. J Natl Compr Canc Netw. 2020; 18(9): 1191–1199.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17): 1714–1768.